The meta-analysis included 28 randomized trials (n=6544). The strongest PFS benefit was observed with sapanisertib plus fulvestrant (HR, 0.34; 95% confidence interval [CI], 0.14–0.82), though this regimen was associated with a discontinuation…
The meta-analysis included 28 randomized trials (n=6544). The strongest PFS benefit was observed with sapanisertib plus fulvestrant (HR, 0.34; 95% confidence interval [CI], 0.14–0.82), though this regimen was associated with a discontinuation…